Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417052 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01417052 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT01417052, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
Interventions
- DRUG 50 mg LX3305 QD
- DRUG 100 mg LX3305 QD
- DRUG 150 mg LX3305 QD
- DRUG 200 mg LX3305 QD
- DRUG 250 mg LX3305 QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01417052
The ClinicalTrials.gov registry entry for NCT01417052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 50 mg LX3305 QD is the first listed.
NCT01417052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01417052 about?
NCT01417052 is a clinical study titled "A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis". The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
What is the current status of trial NCT01417052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01417052?
The interventions under investigation include: 50 mg LX3305 QD (DRUG), 100 mg LX3305 QD (DRUG), 150 mg LX3305 QD (DRUG), 200 mg LX3305 QD (DRUG), 250 mg LX3305 QD (DRUG).
Who is sponsoring clinical trial NCT01417052?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.